Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

Shamia Faison,1 Roberto Gomeni,2 Shannon Mendes,1 Welton O’Neal,1 Stefan Schwabe,1 Azmi Nasser1 1Supernus Pharmaceuticals, Inc., Rockville, MD, USA; 2PharmacoMetrica, La Fouillade, FranceCorrespondence: Azmi NasserSupernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD 20850, U...

Full description

Bibliographic Details
Main Authors: Faison S, Gomeni R, Mendes S, O'Neal W, Schwabe S, Nasser A
Format: Article
Language:English
Published: Dove Medical Press 2020-09-01
Series:Clinical Pharmacology: Advances and Applications
Subjects:
oxcarbazepine
monotherapy
oxtellar
monohydroxy derivative
adjunctive therapy
Online Access:https://www.dovepress.com/predicted-efficacy-of-once-daily-extended-release-oxcarbazepine-oxtell-peer-reviewed-article-CPAA

Internet

https://www.dovepress.com/predicted-efficacy-of-once-daily-extended-release-oxcarbazepine-oxtell-peer-reviewed-article-CPAA

Similar Items